Asian Journal of Biotechnology and Genetic Engineering

Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies

Nand Lal *

Department of Life Sciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur – 208 024, U.P, India.

Priya Prajapati

Department of Life Sciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur – 208 024, U.P, India.

*Author to whom correspondence should be addressed.

---

Abstract

Sickle cell disease (SCD) is a monogenic blood disorder caused by a single nucleotide mutation in the β-globin gene that swaps the hydrophilic glutamic acid at position six with the hydrophobic valine. Haematopoietic stem cell transplantation is the only curative treatment for SCD, but has major risks and problems. Autologous gene therapy, in which "all" gene copy is put into the patient's cells, a faulty gene is fixed, or genes are deactivated, has the advantage of not requiring the patient to find a perfect donor. Gene therapy has been shown to be curative in preclinical and clinical trials. LentiGlobin, a self-inactivating lentiviral vector encoding the human antiserpentine. Haemoglobin Subunit Beta, is now being tested in clinical trials. However, lentiviral vector-based gene therapy poses potential dangers such as Replication-Competent Lentivirus and insertional mutagenesis. Gene editing technologies allow for permanent modification of disease-causing genes, and HSPCs are the therapeutic product for autologous transplantation. CRISPR/Cas9 is a versatile and efficient class of programmable nucleases that use single-stranded guide RNA sequences and the Cas9 endonuclease to attach to a specific target in the genome. Base editors are generated by pairing a nucleotide deaminase with a Cas9 protein that is catalytically suppressed. All four gene editing strategies have been evaluated in HSPCs for the treatment of SCD, including correcting the sickle cell mutation in HBB, producing enough HbF to reverse the sickle shape of the RBC, focusing on the HbF transcriptional repressors, and introducing the advantageous HPF mutations. CRISPR/Cas9 gene editing has been used to treat SCD, including correcting the sickle cell mutation, producing enough HbF to reverse the sickle shape, focusing on HbF transcriptional repressors, and introducing HPFH mutations. Future challenges for the success of CRISPR/Cas9 gene editing include off-target effects, gene repair efficiency, and in vivo transplantation of gene-edited HSPC.

Keywords: CRISPR/Cas9, gene editing, gene therapy, β-globin gene, sickle cell disease, single nucleotide mutation

---

---

---

References

SCD Collaborators. Sickle cell disease collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: A systematic analysis from the global burden of disease study 2021. The Lancet Haematol. 2023;10(8):e585-e599. DOI: 10.1016/S2352-3026(23)00118-7

Moody KL, Mercer K, Glass M. An integrative review of the prevalence of depression among pediatric patients with sickle cell disease. Soc Work Public Health. 2019;34:343-52. DOI: 10.1080/19371918.2019.1606754

Hoppe C, Neumayr L. Sickle Cell Disease: Monitoring, current treatment, and therapeutics under development. Hematol Oncol Clin North Am. 2019;33:355-71. DOI: 10.1016/j.hoc.2019.01.014

Galadanci AA, DeBaun MR, Galadanci NA. Neurologic complications in children under five years with sickle cell disease. Neurosci Lett. 2019;706:201-206. DOI: 10.1016/j.neulet.2019.04.030

Sedrak A, Kondamudi NP. Sickle Cell Disease [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Available: https://www.ncbi.nlm.nih.gov/books/NBK482384/

Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848-55. DOI: 10.1056/NEJMoa1609677

Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617-28. DOI: 10.1056/NEJMoa2117175

Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81. DOI: 10.2174/1566523214666141127095336

Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood. 2018;131(17):1960-73. DOI: 10.1182/blood-2017-10-811505

Grevet JD, Lan X, Hamagami N, Edwards CR, Sankaranarayanan L, Ji X et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science. 2018;361(6399):285-290. DOI: 10.1126/science.aao0932

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21. DOI: 10.1126/science.1225829

Bollag RJ, Waldman AS, Liskay RM. Homologous recombination in mammalian cells. Annu Rev Genet. 1989;23:199-225. DOI: 10.1146/annurev.ge.23.120189.001215

Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 1985;317(6034):230-34. DOI: 10.1038/317230a0

Johnson RD, Jasin M. Double-Strand-break-induced homologous recombination in mammalian cells. Biochem Soc Trans. 2001;29(Pt 2):196-201. DOI: 10.1042/0300-5127:0290196

Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: Prospects and challenges. Nat Med. 2015;21(2):121-31. DOI: 10.1038/nm.3793

Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636-46. DOI: 10.1038/nrg2842

Cathomen T, Keith Joung J. Zinc-finger Nucleases: The Next Generation Emerges. Mol Ther. 2008;16(7):1200-207doi: 10.1038/mt.2008.114

Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells. 2011;29(11):1717-26. DOI: 10.1002/stem.718

Zou J, Mali P, Huang X, Dowey SN, Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011;118(17):4599-608. DOI: 10.1182/blood-2011-02-335554

Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326(5959):1509–12. DOI: 10.1126/science.1178811

Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng. 2014;111(5):1048-53. DOI: 10.1002/bit.25018

Suzuki K, Yu C, Qu J, Li M, Yao X, Yuan T et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell. 2014;15(1):31-36. DOI: 10.1016/j.stem.2014.06.016

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308. DOI: 10.1038/nprot.2013.143

Huang X, Wang Y, Yan W, Smith C, Ye Z, Wang J et al. Production of Gene-corrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells. 2015;33(5):1470-79. DOI: 10.1002/stem.1969

Cottle RN, Lee CM, Archer D, Bao G. Controlled delivery of β-globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection. Sci Rep. 2015;5:16031. Available:https://doi.org/10.1038/srep16031

Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6(5):363-72. DOI: 10.1007/s13238-015-0153-5

Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60(2):174-82. DOI: 10.1007/s00239-004-0046-3

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169(12): 5429-33. DOI: 10.1128/jb.169.12.5429-5433.1987

Mojica FJ, Juez G, Rodríguez-Valera F. Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Mol Microbiol. 1993;9(3):613-21. DOI: 10.1111/j.1365-2958.1993.tb01721.x

Jansen R., van Embden JDA, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75. DOI: 10.1046/j.1365-2958.2002.02839.x

Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471(7340):602-607. DOI: 10.1038/nature09886

Gundry MC, Brunetti L, Lin A, Mayle AE, Kitano A, Wagner D et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep. 2016;17(5):1453-61. DOI: 10.1016/j.celrep.2016.09.092

Li C, Psatha N, Sova P, Gil S, Wang H, Kim J et al. Reactivation of γ-globin in adult β-YAC mice after ex vivo and In vivo hematopoietic stem cell genome editing. Blood. 2018;131(26):2915-928. DOI: 10.1182/blood-2018-03-838540

Liu N, Hargreaves VV, Zhu Q, Kurland JV, Hong J, Kim W et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell. 2018;173(2):430-42.e17. DOI: 10.1016/j.cell.2018.03.016

Humbert O, Peterson CW, Norgaard ZK, Radtke S, Kiem HP. A Nonhuman primate transplantation model to evaluate hematopoietic stem cell gene editing strategies for β-Hemoglobinopathies. Mol Ther Methods Clin Dev. 2018;8:75-86. DOI: 10.1016/j.omtm.2017.11.005

Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019;25(5):776-83. DOI: 10.1038/s41591-019-0401-y

Zeng J, Wu Y, Ren C, Bonanno J, Shen AH, Shea D et al. Therapeutic base editing of human hematopoietic stem cells. Nat Med. 2020; 26(4):535-41. DOI: 10.1038/s41591-020-0790-y

Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet. 2018;50:498–503. DOI: 10.1038/s41588-018-0085-0

Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22(9):987-90. DOI: 10.1038/nm.4170

Humbert O, Radtke S, Samuelson C, Carrillo RR, Perez AM, Reddy SS et al. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. Sci Transl Med. 2019;11(503):eaaw3768. DOI: 10.1126/scitranslmed.aaw3768

Wang L, Li L, Ma Y, Hu H, Li Q, Yang Y et al. Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies. Cell Res. 2020;30:276–78. DOI: 10.1038/s41422-019-0267-z

Weber L, Frati G, Felix T, Hardouin G, Casini A, Wollenschlaeger C et al. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv. 2020;6(7): eaay9392. DOI: 10.1126/sciadv.aay9392

Ye L, Wang J, Tan Y, Beyer AI, Xie F, Muench MO et al. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. Proc Natl Acad Sci USA. 2016;113(38):10661-65. DOI: 10.1073/pnas.1612075113

Lomova A, Clark DN, Campo-Fernandez B, Flores-Bjurström C, Kaufman ML, Fitz-Gibbon S et al. Improving gene editing outcomes in human hematopoietic stem and progenitor cells by temporal control of DNA repair. Stem Cells. 2018; 37:1–11. DOI: 10.1002/stem.2935

Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384-389. DOI: 10.1038/nature20134

Fonfara I, Le Rhun A, Chylinski K, Makarova KS, Lécrivain AL, Bzdrenga J et al. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. 2014;42(4):2577-90. DOI: 10.1093/nar/gkt1074

Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. 2015;33(12):1293-98. DOI: 10.1038/nbt.3404

Chatterjee P, Jakimo N, Jacobson JM. Minimal PAM specificity of a highly similar SpCas9 ortholog. Sci Adv. 2018;4(10): eaau0766. DOI: 10.1126/sciadv.aau0766

Kim S, Koo T, Jee HG, Cho HY, Lee G, Lim DG et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 2018;28(3):367–73. DOI: 10.1101/gr.231936.117

Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249-54. DOI: 10.1038/s41591-018-0326-x

Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. Mol Ther Methods Clin Dev. 2018; 10: 105-12. DOI: 10.1016/j.omtm.2018.06.006

Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-26. DOI: 10.1038/nbt.2623

Chen JS, Dagdas YS, Kleinstiver BP, Welch MM, Sousa AA, Harrington LB et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature. 2017;550(7676):407-10. DOI: 10.1038/nature24268

Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013;31(9):839-43. DOI:10.1038/nbt.2673

Jiang C, Mei M, Li B, Zhu X, Zu W, Tian Y et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 In vivo. Cell Res. 2017;27(3):440-43. DOI: 10.1038/cr.2017.16

Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA et al. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021;13(598):eabf2444. DOI: 10.1126/scitranslmed.abf2444

Schneiderman J, Thompson AA, Walters MC, Kwiatkowski JL, Kulozik AE, Sauer MG et al. Interim results from the phase 3 hgb-207 (northstar-2) and hgb-212 (northstar-3) studies of betibeglogene autotemcel gene therapy (lentiglobin) for the treatment of transfusion-dependent β-thalassemia. Biol Blood Marrow Transplant. 2020;26:S87–S88. DOI: 10.1016/j.bbmt.2019.12.588

Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK et al. CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia. N Engl J Med. 2021;384(3): 252-60. DOI: 10.1056/NEJMoa2031054

Available:https://visiblealpha.com/blog/first-crispr-based-gene-therapy-for-sickle-cell-disease-on-track-for-fda-approval/#:~:text=Two%20gene%20therapy%20treatments%20for%20sickle%20cell%20disease,%E2%80%94%20a%2 major%20milestone%20for%20CRISPR%20gene%20editing.